Women's
Longevity

Healthspan — the period of life spent in full cognitive and physical health — looks different for women than it does for men. The reasons are biological, hormonal, and structural.

Women experience a more dramatic and compressed hormonal transition than men — the perimenopause and menopause transition involves a rapid and significant decline in estrogen and progesterone that affects virtually every system in the body simultaneously. The downstream effects on cardiovascular health, bone density, brain function, metabolic health, sleep, mood, and body composition are profound and interconnected.

Understanding women's longevity requires understanding this transition — not as a disease to be managed but as a biological event with known drivers, known risks, and increasingly well-characterized interventions that can meaningfully alter its trajectory.

It also requires understanding the ways in which women's health risks differ from men's across the lifespan — in cardiovascular disease, autoimmune conditions, thyroid dysfunction, bone health, and cognitive aging — and addressing those differences with the specificity they deserve.

No topic is more central to women's longevity than the hormonal transition — and no topic has been more poorly communicated to the women experiencing it.

Perimenopause begins — on average — in the early to mid forties, though it can start earlier. It is not menopause. It is the transition toward menopause, characterized by fluctuating and gradually declining estrogen and progesterone levels, irregular cycles, and a wide range of symptoms that most women are never told to expect.

Many women experience these symptoms for years before receiving any explanation connecting them to hormonal change. The average time from symptom onset to perimenopause diagnosis remains unacceptably long.

Menopause is defined as twelve consecutive months without a menstrual period. The average age in the United States is 51. It is a single point in time — everything before it is perimenopause, everything after is post-menopause.

Post-menopause — the decades following the final menstrual period — is the phase during which the long-term health consequences of estrogen decline become most significant. Cardiovascular disease risk increases substantially. Bone density loss accelerates. Cognitive changes may become more pronounced. Metabolic health shifts. These are not inevitable outcomes — they are risk factors that can be meaningfully addressed.

Estrogen is far more than a reproductive hormone. It is a systemic protective agent — with receptors in the heart, brain, bones, gut, skin, blood vessels, immune system, and virtually every other tissue in the body.

Its decline at menopause is not simply a reproductive event. It is a systemic biological shift with consequences across every major organ system.

No topic in women's health has been more distorted by a single piece of research than HRT.

The 2002 Women's Health Initiative study triggered a dramatic and lasting decline in HRT prescribing — based on findings that have since been significantly recontextualized. What the original coverage failed to communicate was that the study used synthetic progestins rather than bioidentical progesterone, oral rather than transdermal estrogen, and enrolled women who were on average a decade past menopause — a population for whom the timing of intervention matters enormously.

The current clinical consensus — supported by the Menopause Society, the British Menopause Society, and the majority of menopause specialists worldwide — is that for most healthy women under 60 or within ten years of menopause onset, the benefits of appropriately prescribed HRT meaningfully outweigh the risks.

Testosterone is not a male hormone. Women produce testosterone throughout their lives — in the ovaries and adrenal glands — and it plays a central role in energy, libido, muscle maintenance, bone density, mood, and cognitive function.

Testosterone declines gradually from the late twenties and drops more significantly around perimenopause. Low testosterone in women contributes to fatigue, reduced libido, loss of muscle tone, mood changes, and cognitive symptoms — and is significantly undertreated relative to its prevalence and impact.

Low-dose testosterone therapy for women is an active and growing area of clinical practice with a meaningful evidence base — particularly for libido, energy, and body composition. It is not currently FDA-approved for women in the United States — meaning it is prescribed off-label and typically through compounding pharmacies — but it is widely used in menopause specialist practices and is approved for women in several other countries.

The conversation around testosterone in women has been largely absent from mainstream medicine and wellness alike. That is changing — and it deserves to be covered honestly.

Bone health is one of the most consequential and most overlooked dimensions of women's longevity.

Women reach peak bone mass in their late twenties. From that point the goal is preservation. Estrogen is the primary protector of bone density in women — its loss at menopause triggers a period of accelerated bone loss that can significantly increase fracture risk over the following decades.

Hip fracture in older women is a serious and often life-altering event. The one-year mortality rate following hip fracture is 15-20% — higher than many cancers — and the functional consequences for survivors are profound.

Cardiovascular disease is the leading cause of death in women — yet it remains systematically underdiagnosed, undertreated, and under-researched in female populations.

Women's cardiovascular risk differs from men's in important ways that the medical system has historically failed to account for. Heart attack symptoms present differently in women — less likely to involve classic chest pain, more likely to involve jaw pain, nausea, fatigue, and shortness of breath. Cardiovascular risk assessment tools developed primarily on male populations underestimate risk in women. And the post-menopausal surge in cardiovascular risk is not adequately communicated or addressed in most standard care settings.

The metabolic changes of perimenopause and menopause are among the most frustrating and least explained aspects of the hormonal transition for most women.

Increased abdominal fat accumulation, insulin resistance, and metabolic slowing in perimenopause are not primarily caused by changes in diet or activity — they are driven by hormonal change. Estrogen influences fat distribution, insulin sensitivity, and metabolic rate. Its decline shifts fat storage toward the abdomen — the most metabolically dangerous location — and reduces insulin sensitivity independent of lifestyle.

Understanding this is important not because lifestyle does not matter — it does, significantly — but because women who are blamed for metabolic changes that are hormonally driven are being failed by an incomplete explanation.

Women have higher rates of Alzheimer's disease than men — accounting for approximately two thirds of all Alzheimer's cases. This disparity is not simply a function of women living longer. It is increasingly understood to reflect the biological consequences of estrogen loss on the brain.

The perimenopause transition is associated with measurable changes in brain glucose metabolism — the brain's energy supply — that precede cognitive symptoms by years. These changes are driven in part by estrogen's role in supporting cerebral energy metabolism. Research from the Women's Brain Health Initiative and other institutions is establishing the biological mechanisms with increasing clarity.